30041-95-3

Usage

Uses

Used in Pharmaceutical Industry:
(4-CYANOPHENOXY) ACETIC ACID ETHYL ESTER is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be a building block for the production of other chemicals.
Used in Agrochemical Industry:
(4-CYANOPHENOXY) ACETIC ACID ETHYL ESTER is used as an intermediate in the synthesis of various agrochemicals for its ability to be a building block for the production of other chemicals.
Used in Chemical Industry:
(4-CYANOPHENOXY) ACETIC ACID ETHYL ESTER is used in various chemical reactions and processes for its unique chemical structure and reactivity.
Used in Development of New Drugs:
(4-CYANOPHENOXY) ACETIC ACID ETHYL ESTER is used in the development of new drugs due to its potential applications and unique chemical structure.
Used in Development of Advanced Materials:
(4-CYANOPHENOXY) ACETIC ACID ETHYL ESTER is used in the development of advanced materials due to its potential applications and unique chemical structure.

InChI:InChI=1/C11H11NO3/c1-2-14-11(13)8-15-10-5-3-9(7-12)4-6-10/h3-6H,2,8H2,1H3

Upstream product

• 767-00-0 4-cyanophenol 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 
• 1073-72-9 4-hydroxythioanisole 
• 557-21-1 zinc(II) cyanide 
• 15267-46-6 ethyl 2-(4-methylsulfanylphenoxy)acetate 

Downstream Products

• 1272519-95-5 (Z)-methyl-2-(4-(5-(4-methoxybenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)phenoxy)acetate 
• 1541988-03-7 N-(2-amino-6-chloropyridin-3-yl)-2-(4-cyanophenoxy)acetamide 
• 1541988-05-9 N-[2-amino-6-(4-cyanophenyl)pyridin-3-yl]-2-(4-cyanophenoxy)acetamide 
• 1541988-06-0 4-[2-[(4-cyanophenoxy)methyl]-3H-imidazo[4,5-b]pyridin-5-yl]benzonitrile 
• 1541988-19-5 4-[(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]benzonitrile 
• 1541988-22-0 4-[(5-chloro-3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]benzonitrile 
• 1541988-65-1 4-[(5-chloro-1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methoxy]benzonitrile 
• 1541988-24-2 4-[2-[(4-cyanophenoxy)methyl]-3-methyl-3H-imidazo[4,5-b]-pyridin-5-yl]benzonitrile 
• 1878-82-6 (4-cyanophenoxy)acetic acid 
• 1541987-89-6 N-[2-amino-6-[(4-cyanobenzyl)oxy]pyridin-3-yl]-2-(4-cyanophenoxy)acetamide 
• 55368-68-8 2-(4-cyanophenoxy)acetyl chloride 
• 1541987-92-1 4-[[5-(4-cyanobenzyloxy)-3H-imidazo[4,5-b]pyridin-2-yl]methoxy]benzonitrile 
• 695211-56-4 ethyl 2-(4-(1H-tetrazol-5-yl)phenoxy)acetate 

Relevant academic research and scientific papers

Nickel-Catalyzed Cyanation of Aryl Thioethers

A nickel-catalyzed cyanation of aryl thioethers using Zn(CN)2 as a cyanide source has been developed to access functionalized aryl nitriles. The ligand dcype (1,2-bis(dicyclohexylphosphino)ethane) in combination with the base KOAc (potassium acetate) is essential for achieving this transformation efficiently. This reaction involves both a C-S bond activation and a C-C bond formation. The scalability, low catalyst and reagents loadings, and high functional group tolerance have enabled both late-stage derivatization and polymer recycling, demonstrating the reaction's utility across organic chemistry.

Synthesis and larvicidal activity of 1,3,4-oxadiazole derivatives containing a 3-chloropyridin-2-yl-1H-pyrazole scaffold

Abstract: A new series of 1,3,4-oxadiazole derivatives with a 3-chloropyridin-2-yl-1H-pyrazole moiety was designed, synthesized, and characterized. The results of bioassay against Helicoverpa armigera and Plutella xylostella indicated that some of the synthesized compounds showed remarkable larvicidal activity. In particular, the LC50 values of the most active compounds against P. xylostella were 46.5, 23.9, and 13.9?mg/dm3, and against Helicoverpa armigera were 88.3 and 69.5?mg/dm3, the latter being slightly better than commercial chlorpyrifos (LC50 103.77?mg/dm3). Preliminary SAR was also discussed. Graphical abstract: [Figure not available: see fulltext.].

HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME

The present invention provides compounds I and II and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.

Synthesis and evaluation of 1,4-naphthoquinone ether derivatives as SmTGR inhibitors and new anti-schistosomal drugs

Investigations regarding the chemistry and mechanism of action of 2-methyl-1,4-naphthoquinone (or menadione) derivatives revealed 3-phenoxymethyl menadiones as a novel anti-schistosomal chemical series. These newly synthesized compounds (1-7) and their di

Design and synthesis of heterocyclic cations for specific DNA recognition: From AT-rich to mixed-base-pair DNA sequences

The compounds synthesized in this research were designed with the goal of establishing a new paradigm for mixed-base-pair DNA sequence-specific recognition. The design scheme starts with a cell-permeable heterocyclic cation that binds to AT base pair sites in the DNA minor groove. Modifications were introduced in the original compound to include an H-bond accepting group to specifically recognize the G-NH that projects into the minor groove. Therefore, a series of heterocyclic cations substituted with an azabenzimidazole ring has been designed and synthesized for mixed-base-pair DNA recognition. The most successful compound, 12a, had an azabenzimidazole to recognize G and additional modifications for general minor groove interactions. It binds to the DNA site -AAAGTTT- more strongly than the -AAATTT- site without GC and indicates the design success. Structural modifications of 12a generally weakened binding. The interactions of the new compound with a variety of DNA sequences with and without GC base pairs were evaluated by thermal melting analysis, circular dichroism, fluorescence emission spectroscopy, surface plasmon resonance, and molecular modeling.

Design, synthesis and molecular docking of amide and urea derivatives as Escherichia coli PDHc-E1 inhibitors

By targeting the ThDP binding site of Escherichia coli PDHc-E1, two new 'open-chain' classes of E. coli PDHc-E1 inhibitors, amide and urea derivatives, were designed, synthesized, and evaluated. The amide derivatives of compound 6d, with 4-NO2 in the benzene ring, showed the most potent inhibition of E. coli PDHc-E1. The urea derivatives displayed more potent inhibitory activity than the corresponding amide derivatives with the same substituent. Molecular docking studies confirmed that the urea derivatives have more potency due to the two hydrogen bonds formed by two NH of urea with Glu522. The docking results also indicate it might help us to design more efficient PDHc-E1 inhibitors that could interact with Glu522.

PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PDE9 INHIBITORS

A compound of the general formula (I) wherein R1 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, CN, -O-C1-C3-alkyl, fluorinated -O-C1-C3-alkyl, -(CH2)mOH and 5-membered heterocyclic group with 1 or 2 heteroatoms selected from N, O and S; and 6- or 10-membered heteroaryl with 1 to 3 heteroatoms selected from O, N and S; R2 and R3 independently of each other represent H atom or straight or branched C1-C3 alkyl; R4 is selected from the group consisting of 4- to 6- membered cycloalkyl, wherein one of carbon atoms can be replaced by O atom, and which is unsubstituted or substituted with one or two halogen atoms,and straight or branched C1-C4 alkyl; Q represents a bond or C1-C3-alkylene, which can be optionally substituted by one to three C1-C3-alkyls; X is selected from the group consisting of O, NR5, and S(O)p; R5 represents H atom or C1-C3alkyl; m is 1, 2 or 3; p is 0, 1 or 2; and salts thereof, for use as a medicament, in particular for treating cognitive function disorders and neurodegenerative diseases.

COFERONS AND METHODS OF MAKING AND USING THEM

The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.

A class of 5-benzylidene-2-phenylthiazolinones with high potency as direct 5-lipoxygenase inhibitors

A novel class of potent direct 5-lipoxygenase (5-LO) inhibitors bearing a thiazolinone-scaffold identified by virtual screening is presented. A range of substitutions and the importance of the 2-phenyl moiety were evaluated. This series is characterized by high potency in intact polymorphonuclear leukocytes and a cell-free system, exemplified by (Z)-2-(4-chlorophenyl)-5-(4- methoxybenzylidene)-5H-thiazol-4-one (18, IC50 = 0.28 and 0.09 μ-M). These disubstituted thiazolinones may possess potential for intervention with inflammatory and allergic diseases and certain cancer types.

Cis-imidazolines

The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and